Xtandi (enzalutamide) is a small molecule pharmaceutical. Enzalutamide was first approved as Xtandi on 2012-08-31. It is used to treat prostatic neoplasms in the USA. It has been approved in Europe to treat prostatic neoplasms. The pharmaceutical is active against androgen receptor. Xtandi's patents are valid until 2027-08-13 (FDA).
|Drug Class||Non-steroid antiandrogens|